Literature DB >> 3500063

Synergistic interaction between interleukin 4 and anti-Bp50 (CDw40) revealed in a novel B cell restimulation assay.

J Gordon1, M J Millsum, G R Guy, J A Ledbetter.   

Abstract

Highly purified resting B lymphocytes stimulated for 3 days to high-rate DNA synthesis by a synergistic combination of phorbol dibutyrate and ionomycin soon returned to quiescence once those signals had been removed. The maintenance of DNA synthesis in such cultures was found to provide a sensitive assay for revealing the factors that interact with cycling B cells. Whereas several activities-namely, interleukin 4, anti-Bp50 and a low molecular weight B cell growth factor-were, by themselves, capable of prolonging DNA synthesis over a further day or so, no single factor was capable of sustaining the replication cycle out to day 6 of culture. By contrast, certain combinations of activities displayed significant synergy in the restimulation assay. The most striking observed was that between interleukin 4 and anti-Bp50 where, by day 6, their combined effect on maintaining DNA synthesis in 3-day stimulated cells was the same as having kept phorbol dibutyrate and ionomycin in the culture system. The implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500063     DOI: 10.1002/eji.1830171026

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

Review 1.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

2.  Phorbol ester and calcium ionophore are sufficient to promote cell replication in cultures of quiescent human B lymphocytes.

Authors:  L Flores-Romo; D Foster; G R Guy; J Gordon
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

3.  Mitogenic stimulation of human B lymphocytes via the inositol phospholipid 'dual pathway' of signalling requires persistent activation of both second messenger arms.

Authors:  J Gordon; G R Guy; M J Millsum
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

4.  Immunoglobulin isotype production by cycling human B lymphocytes in response to recombinant cytokines and anti-IgM.

Authors:  L Flores-Romo; M J Millsum; S Gillis; P Stubbs; C Sykes; J Gordon
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

5.  Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes.

Authors:  K Kotowicz; G L Dixon; N J Klein; M J Peters; R E Callard
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

6.  CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency.

Authors:  M Farrington; L S Grosmaire; S Nonoyama; S H Fischer; D Hollenbaugh; J A Ledbetter; R J Noelle; A Aruffo; H D Ochs
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

7.  Deficiencies in the CD40 and CD154 receptor-ligand system reduce experimental lung metastasis.

Authors:  Susan Blaydes Ingersoll; Florian Langer; Jamie M Walker; Todd Meyer; Theresa Robson; Mildred Amaya; Hina Desai; John L Francis; Ali Amirkhosravi
Journal:  Clin Exp Metastasis       Date:  2009-07-30       Impact factor: 5.150

8.  Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells.

Authors:  V A Boussiotis; L M Nadler; J L Strominger; A E Goldfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction.

Authors:  D Gray; P Dullforce; S Jainandunsing
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

10.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity.

Authors:  D Hollenbaugh; L S Grosmaire; C D Kullas; N J Chalupny; S Braesch-Andersen; R J Noelle; I Stamenkovic; J A Ledbetter; A Aruffo
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.